The U.S. Food and Drug Administration (FDA) has issued a high-risk recall notice for several Draeger mechanical filters used during anesthesia and mechanical ventilation. The agency is advising hospitals to stop using the affected devices after reports of serious injuries linked to inaccurate carbon dioxide readings.
The recall covers the SafeStar and TwinStar filter models, which are designed to protect patients from bacterial and viral contamination during surgery or intensive care treatment. These devices also include ports for capnography, a critical monitoring method used to measure the amount of carbon dioxide a patient exhales while under anesthesia.
According to the FDA, the recalled filters can cause misleading carbon dioxide readings. This may lead healthcare providers to believe a patient is experiencing abnormal levels of carbon dioxide and prompt them to administer unnecessary or harmful treatments. In its recall notice, the agency noted that serious injuries have been reported, though it did not disclose the number of cases. No deaths have been linked to the issue.
The FDA’s enforcement report states that Draeger began recalling the devices in June 2025. On July 22, the company sent updated notices to customers, advising them to immediately stop using the affected products and remove them from their inventory. Hospitals were instructed to contact a Draeger representative to return and replace the filters.
In total, nearly 12 million devices are included in the recall, covering four different filter models. The FDA classified the action in its highest risk category due to the potential for severe harm. The agency explained that the problem occurs when the sampling port of the filter is used, which can result in a slow increase of the carbon dioxide curve. This could delay diagnosis, lead to incorrect treatment decisions, and potentially cause airway injury, brain injury, or death.
The recalled filters are used widely in operating rooms and intensive care units, making the potential impact significant. While no fatalities have been reported, the nature of the injuries described underscores the seriousness of the situation. For hospitals and surgical centers, the removal of these devices will require immediate operational adjustments to ensure patient safety and continuity of care.
This incident also highlights the importance of proactive device monitoring and regulatory oversight in the healthcare industry. Medical devices that perform critical functions, such as patient ventilation and monitoring, require rigorous testing and quality assurance both before and after they reach the market. Early identification of performance issues, coupled with prompt corrective actions, can help prevent patient harm and maintain trust in medical technology.
At EMMA International, we work with life sciences companies to strengthen their quality management systems and ensure compliance with regulatory requirements worldwide. Recalls such as this one underscore the need for robust risk management strategies, thorough post-market surveillance, and rapid response protocols when issues arise. By helping manufacturers implement and maintain effective quality processes, EMMA International supports the development and delivery of safe, effective medical products that meet both regulatory standards and patient needs.
For more information on how EMMA International can assist, visit www.emmainternational.com. Contact EMMA International at (248) 987-4497 or by email at info@emmainternational.com to learn more.
References
MedTech Dive, “Draeger removes ventilation filters over misleading carbon dioxide readings,” August 12, 2025.
